Valeant Pharmaceuticals International, Inc. (NYSE:VRX) [Trend Analysis] attempts to attain leading position in street, Shares price changes as it -5.05% to close at $14.68 with the total traded volume of 21.97 Million shares. Valeant Pharmaceuticals International, Inc. (NYSE:VRX) reported that its positive results from a Phase 3, multicenter double-blind, randomized, vehicle-controlled clinical study to assess the safety and efficacy of IDP-118 lotion in the treatment of plaque psoriasis.
Within the Phase 3 study of 215 adult subjects with moderate to severe psoriasis, IDP-118 showed statistical significance to vehicle with a treatment success rate of 45.33% and a p<0.001. The primary endpoint of the 12-week study was achievement of a “clear” to “almost clear” score based on an Investigator Global Assessment (IGA) at 8 weeks, and at least 2 grade improvement in the IGA at weeks 12, 6, 4 and 2 as secondary endpoints. The firm has institutional ownership of 66.80%, while insider ownership included 2.30%. Its price to sales ratio ended at 0.50. VRX attains analyst recommendation of 3.00 with week performance of -4.30%.
Polar Power, Inc. (NASDAQ:POLA) has closed its previously declared initial public offering of 2,400,000 shares of its common stock at a public offering price of $7.00 per share. In connection with the initial public offering, the underwriters exercised their over-allotment option to purchase an additional 360,000 shares at the initial public offering price, less the underwriting discount, in full.
A registration statement relating to these securities was declared effective by the U.S. Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.